Biogen and Sage Therapeutics collaboration Develop Zurzvae It proved fruitful.of FDA approved It is an oral medicine specifically designed for the treatment of postpartum depression (PPD) and is the first antidepressant available specifically for new mothers. According to a CDC study, 1 in 8 women will experience symptoms of postpartum depression. PPD symptoms can be very violent after birth and can be dangerous because they can interfere with the new mother’s functioning. The long-awaited approval came thanks to two randomized, double-blind trials that proved the drug’s efficacy.
A key feature of Zurzvae is that the drug can be effective in just a few days and is supposed to be taken for up to two weeks. Until the advent of once-daily oral tablets, the most common treatment regimen for PPD required him to have an IV injection. This meant that it had to be administered by a healthcare worker in a hospital or health care facility. This approval will allow Zurzuvae to expand access and reach more women in the process of being discharged from hospital.
The problem is that the drug can affect a patient’s ability to drive and cause extreme drowsiness. Additionally, the drug’s warning label emphasizes that, like most antidepressants, the drug may increase the risk of suicidal thoughts. In addition, thrush can harm an unborn baby. Patients taking the drug should use contraception while taking the pill and for 1 week after taking the dregs.
